A new treatment strategy in cancer has been discovered: collateral lethality!

Among the 10 hallmarks of cancer are abnormalities in genetic structure. To multiply rapidly and spread to other tissues, cancer cells silence growth-inhibiting tumor suppressor genes . However, in doing so, genes surrounding the tumor suppressor gene are also inactivated. This is called collateral lethality . Recent research has shown that collateral lethality may be an effective strategy for cancer treatment. In seeking an equivalent in our language, terms such as “secondary / side / multilateral lethality” emerge.
Tumor suppressor genes are the most important protectors against cancer formation. When they are damaged, a cell begins to become cancerous. In most human cancers, tumor suppressor genes have been found to undergo mutation . It had been established that when cancer cells silence their tumor suppressor genes, they also silence surrounding genes. The diagram below shows the mechanism of collateral lethality in cancer.

Diagram explanation: In normal cells, two different pathways perform the same biochemical process. Inactivating one pathway does not prevent the biochemical process. In cancer cells, however, because one of the genes controlling the same biochemical pathway is silenced, the cancer cell becomes dependent on the other gene. This offers us an effective drug target. Inhibiting the activity of this gene or the enzyme it encodes may inhibit cancer cell growth.
Naturepublished a study indicating that, particularly in pancreatic cancer , collateral lethality may be an effective treatment strategy. The study investigated collateral lethality in pancreatic cancer. Of every 3 pancreatic cancers, 1 contains a mutated SMAD4 gene; the activity of neighboring genes was examined. According to the research results:
Neighboring SMAD4, the ME2 gene was also found to be silenced. ME2 is the gene that enables production of enzymes required for cancer cells’ energy generation. Cancer cells find a solution by keeping the ME3 gene active. Treatments targeting ME3 may therefore enable cancer cells to be destroyed.
What does this study mean clinically?
- A new treatment strategy in cancer has been identified. By identifying the collateral lethality mechanism in each cancer type, new drug targets may be discovered.
- This study has once again demonstrated the importance of genes in treating cancer effectively.
Sources
Collateral Lethality: A New Therapeutic Strategy in Oncology.
Trends in Cancer , Volume 1 , Issue 3 , 161 - 173.
2- Prasenjit Dey, Joelle Baddour, Florian Muller et al.
Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer.
Nature 542, 119-123 (February 2017)
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.